Clinical Efficacy and Safety of Butylphthalide Combined with Vinpocetine in the Treatment of Posterior Circulation Ischemic Vertigo Caused by the Dominant Vertebral Artery
Abstract:【Objective】To evaluate the efficacy and safety of butylphthalide combined with vinpocetine in the treatment of Posterior Circulation Ischemic Vertigo (PCIV) caused by the dominant vertebral artery.【Methods】Eighty-two cases of PCIV patients caused by the dominant vertebral artery were randomly divided into two groups: the control group (n=41) received vinpocetine therapy, and the experimental group (n=41) received butylphthalide combined with vinpocetine therapy. The clinical efficacy and side effects of the two groups were compared. 【Results】The cure rate and total effective rate of patients in the experimental group was 48.78% and 92.68%, respectively, and were significantly higher than for patients in the control group 29.27% and 80.49%, respectively. After treatment, the Vm of the bilateral vertebral artery (LVA, RVA), of the bilateral posterior cerebral artery (LPCA, RPCA), and of the basilar artery (BA) was significantly higher in the experimental group than in the control group. The hemorheology indexes (WBV, PV, and PAI) were significantly lower in the experimental group than in the control group, the differences between the two groups being statistically significant (P<0.05). 【Conclusion】It's safe and effective to use the combination of of butylphthalide and vinpocetine for treatment of PCIV caused by the dominant vertebral artery. The combined treatment can effectively improve the hemorheological and posterior circulation ischemic symptoms of patients.
龚建祖,程伟. 丁苯酞联合长春西汀治疗椎动脉优势型后循环缺血性眩晕的疗效及安全性分析[J]. 医学临床研究, 2016, 33(11): 2088-2091.
GONG Jian-zu, CHENG Wei. Clinical Efficacy and Safety of Butylphthalide Combined with Vinpocetine in the Treatment of Posterior Circulation Ischemic Vertigo Caused by the Dominant Vertebral Artery. JOURNAL OF CLINICAL RESEARCH, 2016, 33(11): 2088-2091.
[1] 冯亚忠,陈娇.长春西汀治疗后循环缺血性眩晕临床分析[J].中华全科医学,2012,10(4):527-528.
[2] 陆耀军,王云霞,李旺俊等.椎动脉优势与后循环缺血性眩晕的关系[J].中国神经免疫学和神经病学杂志,2013,20(4):253-255,259.
[3] 郭岩林.丁苯酞胶囊联合长春西汀治疗后循环缺血性眩晕的疗效观察[J].中国社区医师(医学专业),2013,15(10):52.
[4] C. A. Megnigbeto, R. Launois and J.-P. Sauvage.The European Evaluation of Vertigo scale (EEV) : A clinical validation study[J].Rev Laryngol Otol Rhinol,2001,122 (2) :95-102.
[5] 中华神经科学会,中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经外科杂志,1996,29(6):379-380.
[6] 吴江,贾建平,崔丽英.神经病学[M].北京:人民卫生出版社,2005:151-158.
[7] 宋晓蓉,汪利娟.复方地龙胶囊添加治疗对后循环缺血性眩晕的疗效观察[J].浙江临床医学,2014,16(10):1627-1628.
[8] 阳娜.丁苯酞软胶囊治疗椎动脉优势型眩晕疗效观察[J].国际神经病学神经外科学杂志,2014,41(5):430-432.
[9] Jeon KI,Xu X,Aizawa T,et al.Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism[J].Proc Natl Acad Sci USA,2010,107(21):9795-9800.
[10] Sitges M.Single and combined effects of carbamazepine and vinpocetine on depolarization-induced changes in Na+, Ca2+ and glutamate release in hippocampal isolated nerve endings.[J].Neurochem Intern,2006,49(1):55-61.
[11] 刘曙东,刘全生,付红梅,等.丁苯酞治疗后循环缺血性眩晕的临床研究[J].中华全科医学,2011,9(9):1363-1364.
[12] Li J,Li Y,Ogle M,et al.DL-3-n-butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway.[J].Brain Res,2010,1359:216-226.
[13] 李冉冉,徐鸿华.长春西汀注射液治疗后循环缺血性眩晕的临床疗效[J].中国现代应用药学,2015,32(1):104-107.
[14] 韩卓娅,吕丰收.丁基苯酞软胶囊联合长春西汀治疗后循环缺血眩晕120例分析[J].中国实用神经疾病杂志,2012,15(15):62-63.